Robert W. Baird Analysts Give PRA Health Sciences (PRAH) a $94.00 Price Target

Robert W. Baird set a $94.00 target price on PRA Health Sciences (NASDAQ:PRAH) in a research note issued to investors on Friday morning. The firm currently has a buy rating on the medical research company’s stock.

A number of other analysts have also recently commented on PRAH. Credit Suisse Group boosted their target price on shares of PRA Health Sciences from $80.00 to $84.00 and gave the company an outperform rating in a report on Tuesday, August 8th. SunTrust Banks restated a buy rating on shares of PRA Health Sciences in a report on Wednesday, August 9th. Citigroup restated a buy rating and set a $93.00 target price (up previously from $90.00) on shares of PRA Health Sciences in a report on Thursday, August 10th. Jefferies Group restated a buy rating and set a $92.00 target price (up previously from $88.00) on shares of PRA Health Sciences in a report on Thursday, August 10th. Finally, Zacks Investment Research cut shares of PRA Health Sciences from a hold rating to a sell rating in a report on Friday, August 11th. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $89.09.

Shares of PRA Health Sciences (NASDAQ PRAH) traded down $0.52 during mid-day trading on Friday, hitting $81.85. 460,200 shares of the stock were exchanged, compared to its average volume of 528,596. PRA Health Sciences has a 1 year low of $51.16 and a 1 year high of $84.38. The company has a market cap of $5,186.81, a PE ratio of 30.09, a PEG ratio of 1.42 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 1.38.

PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Wednesday, October 25th. The medical research company reported $0.88 EPS for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.03. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The firm had revenue of $494.55 million for the quarter, compared to analysts’ expectations of $477.89 million. During the same quarter in the previous year, the business posted $0.64 EPS. The company’s quarterly revenue was up 23.7% on a year-over-year basis. equities research analysts expect that PRA Health Sciences will post 3.2 earnings per share for the current year.

In other news, Director Matthew P. Young sold 5,115 shares of PRA Health Sciences stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $79.90, for a total value of $408,688.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.10% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of PRAH. First Bank & Trust raised its position in PRA Health Sciences by 1.6% in the 2nd quarter. First Bank & Trust now owns 3,211 shares of the medical research company’s stock worth $241,000 after buying an additional 52 shares during the last quarter. Renaissance Group LLC raised its position in PRA Health Sciences by 2.5% in the 2nd quarter. Renaissance Group LLC now owns 5,239 shares of the medical research company’s stock worth $393,000 after buying an additional 126 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its position in PRA Health Sciences by 1.9% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 8,505 shares of the medical research company’s stock worth $638,000 after buying an additional 160 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in PRA Health Sciences by 12.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after buying an additional 160 shares during the last quarter. Finally, Smith Asset Management Group LP raised its position in PRA Health Sciences by 0.5% in the 2nd quarter. Smith Asset Management Group LP now owns 61,115 shares of the medical research company’s stock worth $4,584,000 after buying an additional 320 shares during the last quarter. 98.49% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This news story was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/12/04/robert-w-baird-analysts-give-pra-health-sciences-prah-a-94-00-price-target.html.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply